BC Innovations | Jul 17, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Influenza virus Cell culture and mouse studies suggest virus-targeted delivery of defective versions of viral RNA polymerase subunits PA, PB1 and PB2 genes could help prevent or treat influenza A infection. In canine and...
BC Week In Review | Jan 12, 2018
Clinical News

Innovation's Brilacidin-OM meets in Phase II for oral mucocitis

Innovation Pharmaceuticals Inc. (OTCQB:IPIX) reported top-line data from 46 patients receiving chemoradiation for head and neck cancer in the modified intent-to-treat (mITT) population of a Phase II trial showing that thrice-daily 45 mg/15 mL Brilacidin-OM...
BC Innovations | Oct 31, 2017
Distillery Therapeutics


INDICATION: Graft-versus-host disease (GvHD) Mouse studies suggest RSPO1 and DEFA1 could help prevent GvHD-induced gut dysbiosis. In a mouse model of GvHD, RSPO1 delivered before and after disease induction decreased dysbiosis and intestinal pathology compared...
BC Extra | Oct 27, 2017
Preclinical News

RSPO1 restores gut biome in GvHD

Researchers at Hokkaido University (Sapporo, Japan) and colleagues found that R-Spondin 1 ( RSPO1 ) stimulates differentiation of Paneth cells in the intestine, which secrete antimicrobial alpha defensins. The research, published in the Journal of Experimental Medicine...
BC Week In Review | May 24, 2017
Clinical News

Cellceutix completes enrollment in Phase II for ulcerative proctitis

Cellceutix Corp. (OTCQB:CTIX) completed enrollment of 17 patients with mild to moderate ulcerative proctitis or proctosigmoiditis in a Phase II trial evaluating once-daily 50, 100 and 200 mg brilacidin via retention enema for 6 weeks....
BC Week In Review | Jun 27, 2016
Clinical News

Brilacidin: Phase II started

Cellceutix began an observer-blind Phase II trial to evaluate 3 dose levels of once-daily brilacidin given via retention enema for 6 weeks in 18 patients. Cellceutix Corp. (OTCQB:CTIX), Beverly, Mass.   Product: Brilacidin   Business:...
BC Innovations | Jan 28, 2016
Distillery Therapeutics

Therapeutics: Chemokine CC motif ligand 5 (RANTES; CCL5); defensin α 1 (DEFA1; HNP-1)

Cardiovascular disease INDICATION: Inflammation; myocardial infarction (MI) Cell and mouse studies identified a peptide inhibitor of DEFA1- RANTES binding that could help treat MI and inflammation. In a proximity ligation assay in human endothelial cells,...
BC Innovations | Jun 25, 2015
Distillery Techniques

Techniques: SNPs within defensin α 1 (DEFA1; HNP-1)/defensin β 1 (DEFB1) gene cluster and other loci as risk markers for IgA nephropathy

Biomarkers DEFA1 DEFB1 defensin HNP-1 Sun Yat-sen University...
BC Week In Review | Jun 15, 2015
Clinical News

Brilacidin-OM: Phase II started

Cellceutix began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate Brilacidin-OM oral rinse thrice daily for up to 7 weeks in 60 patients with head and neck cancer undergoing chemoradiation. Cellceutix Corp. (OTCQB:CTIX), Beverly,...
BioCentury | Feb 23, 2015
Emerging Company Profile

Eyeing new antibiotics

Traditional antibiotics kill bacteria by inhibiting protein, DNA, or cell wall synthesis but require multiplying cells to be effective. SinSa Laboratories Inc .'s peptide antibiotics kill slow- and fast-growing bacteria by direct disruption of the...
Items per page:
1 - 10 of 71